CN112924666A - Solid support coating product, preparation method, application and product thereof - Google Patents
Solid support coating product, preparation method, application and product thereof Download PDFInfo
- Publication number
- CN112924666A CN112924666A CN201911238160.9A CN201911238160A CN112924666A CN 112924666 A CN112924666 A CN 112924666A CN 201911238160 A CN201911238160 A CN 201911238160A CN 112924666 A CN112924666 A CN 112924666A
- Authority
- CN
- China
- Prior art keywords
- antigen
- virus
- solid support
- virus antigen
- hepatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007787 solid Substances 0.000 title claims abstract description 62
- 238000000576 coating method Methods 0.000 title claims abstract description 53
- 239000011248 coating agent Substances 0.000 title claims abstract description 49
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 34
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 6
- 239000000427 antigen Substances 0.000 claims description 172
- 102000036639 antigens Human genes 0.000 claims description 170
- 108091007433 antigens Proteins 0.000 claims description 170
- 230000005291 magnetic effect Effects 0.000 claims description 104
- 239000011324 bead Substances 0.000 claims description 89
- 235000018102 proteins Nutrition 0.000 claims description 46
- 108090000623 proteins and genes Proteins 0.000 claims description 46
- 102000004169 proteins and genes Human genes 0.000 claims description 46
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 20
- 241000700605 Viruses Species 0.000 claims description 19
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 18
- 230000004913 activation Effects 0.000 claims description 16
- 239000003550 marker Substances 0.000 claims description 16
- 208000035473 Communicable disease Diseases 0.000 claims description 15
- 208000015181 infectious disease Diseases 0.000 claims description 15
- 238000012360 testing method Methods 0.000 claims description 14
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 10
- 235000014633 carbohydrates Nutrition 0.000 claims description 10
- 230000000903 blocking effect Effects 0.000 claims description 9
- 150000001720 carbohydrates Chemical group 0.000 claims description 9
- 230000000747 cardiac effect Effects 0.000 claims description 9
- 230000009870 specific binding Effects 0.000 claims description 9
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 claims description 8
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 8
- 239000004033 plastic Substances 0.000 claims description 8
- 229920003023 plastic Polymers 0.000 claims description 8
- 102000004856 Lectins Human genes 0.000 claims description 7
- 108090001090 Lectins Chemical group 0.000 claims description 7
- 239000002523 lectin Chemical group 0.000 claims description 7
- 241000709687 Coxsackievirus Species 0.000 claims description 6
- 241000711549 Hepacivirus C Species 0.000 claims description 6
- 241000700721 Hepatitis B virus Species 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 239000004793 Polystyrene Substances 0.000 claims description 6
- 229960002685 biotin Drugs 0.000 claims description 6
- 239000011616 biotin Substances 0.000 claims description 6
- 206010014599 encephalitis Diseases 0.000 claims description 6
- 229920002223 polystyrene Polymers 0.000 claims description 6
- 108010010803 Gelatin Proteins 0.000 claims description 5
- 208000037262 Hepatitis delta Diseases 0.000 claims description 5
- 241000724709 Hepatitis delta virus Species 0.000 claims description 5
- 235000020958 biotin Nutrition 0.000 claims description 5
- 239000005018 casein Substances 0.000 claims description 5
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 5
- 235000021240 caseins Nutrition 0.000 claims description 5
- 229920000159 gelatin Polymers 0.000 claims description 5
- 239000008273 gelatin Substances 0.000 claims description 5
- 235000019322 gelatine Nutrition 0.000 claims description 5
- 235000011852 gelatine desserts Nutrition 0.000 claims description 5
- 230000002757 inflammatory effect Effects 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 108090001008 Avidin Proteins 0.000 claims description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 4
- 108010076119 Caseins Proteins 0.000 claims description 4
- 108020004635 Complementary DNA Chemical group 0.000 claims description 4
- 239000000020 Nitrocellulose Substances 0.000 claims description 4
- 229940098773 bovine serum albumin Drugs 0.000 claims description 4
- 239000012636 effector Substances 0.000 claims description 4
- 239000002532 enzyme inhibitor Substances 0.000 claims description 4
- -1 epididymin 4 Proteins 0.000 claims description 4
- 239000011521 glass Substances 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 239000011859 microparticle Substances 0.000 claims description 4
- 229920001220 nitrocellulos Polymers 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 229910052710 silicon Inorganic materials 0.000 claims description 4
- 239000010703 silicon Substances 0.000 claims description 4
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims description 4
- VMSLCPKYRPDHLN-UHFFFAOYSA-N (R)-Humulone Chemical compound CC(C)CC(=O)C1=C(O)C(CC=C(C)C)=C(O)C(O)(CC=C(C)C)C1=O VMSLCPKYRPDHLN-UHFFFAOYSA-N 0.000 claims description 3
- 102000016752 1-Alkyl-2-acetylglycerophosphocholine Esterase Human genes 0.000 claims description 3
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 claims description 3
- 108010024976 Asparaginase Proteins 0.000 claims description 3
- 241000589969 Borreliella burgdorferi Species 0.000 claims description 3
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 claims description 3
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 claims description 3
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 claims description 3
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 3
- 102100032752 C-reactive protein Human genes 0.000 claims description 3
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 claims description 3
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 3
- 108010075016 Ceruloplasmin Proteins 0.000 claims description 3
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 3
- 241001647372 Chlamydia pneumoniae Species 0.000 claims description 3
- 241001647378 Chlamydia psittaci Species 0.000 claims description 3
- 241000606153 Chlamydia trachomatis Species 0.000 claims description 3
- 102000004420 Creatine Kinase Human genes 0.000 claims description 3
- 108010042126 Creatine kinase Proteins 0.000 claims description 3
- 239000003154 D dimer Substances 0.000 claims description 3
- 208000001490 Dengue Diseases 0.000 claims description 3
- 206010012310 Dengue fever Diseases 0.000 claims description 3
- 241001466953 Echovirus Species 0.000 claims description 3
- 239000004593 Epoxy Substances 0.000 claims description 3
- 102000030914 Fatty Acid-Binding Human genes 0.000 claims description 3
- 241000531123 GB virus C Species 0.000 claims description 3
- 101710122194 Gene 2 protein Proteins 0.000 claims description 3
- 102000003886 Glycoproteins Human genes 0.000 claims description 3
- 108090000288 Glycoproteins Proteins 0.000 claims description 3
- 102000014702 Haptoglobin Human genes 0.000 claims description 3
- 108050005077 Haptoglobin Proteins 0.000 claims description 3
- 241000590002 Helicobacter pylori Species 0.000 claims description 3
- 241000724675 Hepatitis E virus Species 0.000 claims description 3
- 241000709721 Hepatovirus A Species 0.000 claims description 3
- 108010033040 Histones Proteins 0.000 claims description 3
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 3
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims description 3
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims description 3
- 241000701806 Human papillomavirus Species 0.000 claims description 3
- 102000004889 Interleukin-6 Human genes 0.000 claims description 3
- 108090001005 Interleukin-6 Proteins 0.000 claims description 3
- 108010044467 Isoenzymes Proteins 0.000 claims description 3
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 claims description 3
- 108010066302 Keratin-19 Proteins 0.000 claims description 3
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 claims description 3
- 241000712079 Measles morbillivirus Species 0.000 claims description 3
- 241000711386 Mumps virus Species 0.000 claims description 3
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 3
- 241000204031 Mycoplasma Species 0.000 claims description 3
- 241000202934 Mycoplasma pneumoniae Species 0.000 claims description 3
- 102000003896 Myeloperoxidases Human genes 0.000 claims description 3
- 108090000235 Myeloperoxidases Proteins 0.000 claims description 3
- 102100030856 Myoglobin Human genes 0.000 claims description 3
- 108010062374 Myoglobin Proteins 0.000 claims description 3
- 108010058846 Ovalbumin Proteins 0.000 claims description 3
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 3
- 208000030852 Parasitic disease Diseases 0.000 claims description 3
- 108010039918 Polylysine Proteins 0.000 claims description 3
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 claims description 3
- 108010048233 Procalcitonin Proteins 0.000 claims description 3
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 3
- 102100038358 Prostate-specific antigen Human genes 0.000 claims description 3
- 241000711798 Rabies lyssavirus Species 0.000 claims description 3
- 101710137426 Replication-associated protein G2P Proteins 0.000 claims description 3
- 241000710799 Rubella virus Species 0.000 claims description 3
- 108700028909 Serum Amyloid A Proteins 0.000 claims description 3
- 102000054727 Serum Amyloid A Human genes 0.000 claims description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 3
- 241000589886 Treponema Species 0.000 claims description 3
- 102000004903 Troponin Human genes 0.000 claims description 3
- 108090001027 Troponin Proteins 0.000 claims description 3
- 241000202921 Ureaplasma urealyticum Species 0.000 claims description 3
- 241000710886 West Nile virus Species 0.000 claims description 3
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims description 3
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims description 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 3
- 229940009550 c1 esterase inhibitor Drugs 0.000 claims description 3
- 208000028512 chlamydia infectious disease Diseases 0.000 claims description 3
- 229940038705 chlamydia trachomatis Drugs 0.000 claims description 3
- 208000025729 dengue disease Diseases 0.000 claims description 3
- 230000002124 endocrine Effects 0.000 claims description 3
- 108091022862 fatty acid binding Proteins 0.000 claims description 3
- 108010052295 fibrin fragment D Proteins 0.000 claims description 3
- 208000024386 fungal infectious disease Diseases 0.000 claims description 3
- 108010083422 gastrin-releasing peptide precursor Proteins 0.000 claims description 3
- 229940037467 helicobacter pylori Drugs 0.000 claims description 3
- 108060003552 hemocyanin Proteins 0.000 claims description 3
- 102000044308 human HPG-1 Human genes 0.000 claims description 3
- 108700014039 human HPG-1 Proteins 0.000 claims description 3
- 229940100601 interleukin-6 Drugs 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical group C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 claims description 3
- 229940092253 ovalbumin Drugs 0.000 claims description 3
- 229920000656 polylysine Polymers 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000002243 precursor Substances 0.000 claims description 3
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 claims description 3
- 235000020183 skimmed milk Nutrition 0.000 claims description 3
- 108010088201 squamous cell carcinoma-related antigen Proteins 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims description 3
- 239000002753 trypsin inhibitor Substances 0.000 claims description 3
- 239000012137 tryptone Substances 0.000 claims description 3
- 241000712461 unidentified influenza virus Species 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 241000224016 Plasmodium Species 0.000 claims description 2
- 241000223996 Toxoplasma Species 0.000 claims description 2
- 241000223104 Trypanosoma Species 0.000 claims description 2
- 230000027455 binding Effects 0.000 claims description 2
- 239000010419 fine particle Substances 0.000 claims description 2
- 239000004816 latex Substances 0.000 claims description 2
- 229920000126 latex Polymers 0.000 claims description 2
- 230000008878 coupling Effects 0.000 abstract description 15
- 238000010168 coupling process Methods 0.000 abstract description 15
- 238000005859 coupling reaction Methods 0.000 abstract description 15
- 238000003018 immunoassay Methods 0.000 abstract description 6
- 239000000047 product Substances 0.000 description 37
- 239000000243 solution Substances 0.000 description 32
- 238000005406 washing Methods 0.000 description 29
- 238000002156 mixing Methods 0.000 description 21
- 239000000203 mixture Substances 0.000 description 13
- 239000000872 buffer Substances 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 230000003213 activating effect Effects 0.000 description 9
- 239000011259 mixed solution Substances 0.000 description 8
- 238000003908 quality control method Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 239000004005 microsphere Substances 0.000 description 6
- 239000003761 preservation solution Substances 0.000 description 6
- 239000012224 working solution Substances 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- QYYMDNHUJFIDDQ-UHFFFAOYSA-N 5-chloro-2-methyl-1,2-thiazol-3-one;2-methyl-1,2-thiazol-3-one Chemical compound CN1SC=CC1=O.CN1SC(Cl)=CC1=O QYYMDNHUJFIDDQ-UHFFFAOYSA-N 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102100033620 Calponin-1 Human genes 0.000 description 4
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 4
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 4
- 101710120037 Toxin CcdB Proteins 0.000 description 4
- 239000012190 activator Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 4
- ATGUDZODTABURZ-UHFFFAOYSA-N thiolan-2-ylideneazanium;chloride Chemical compound Cl.N=C1CCCS1 ATGUDZODTABURZ-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000009191 jumping Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000006249 magnetic particle Substances 0.000 description 3
- 238000007885 magnetic separation Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- CHZVREGLAPRBDI-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) cyclohexanecarboxylate Chemical compound C1CCCCC1C(=O)ON1C(=O)CCC1=O CHZVREGLAPRBDI-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 238000002038 chemiluminescence detection Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
Abstract
The invention relates to the field of immunodetection, and particularly provides a solid support coated product, and a preparation method, application and a product thereof. The method for coating the target molecules by the solid support can reduce the incorrect coupling of the solid support and the target molecules and improve the effective coupling efficiency; the influence of reagents used in the coating process on the structure and stability of the target molecule can be reduced; improving the stability of the coated product. The coating product of the invention can improve the performance index of immunoassay.
Description
Technical Field
The invention relates to the field of immunodetection, and in particular relates to a solid support coated product, a preparation method, application and a product thereof.
Background
In immunoassays, the solid support is coated with a moiety that allows specific binding to achieve capture and separation of the desired analyte. The material of the solid support is, for example, a plastic (e.g., polystyrene, polyvinyl chloride), a derivatized plastic, a magnetic or non-magnetic metal, glass or silicon, and the configuration of the solid support is, for example, a particle, bead, test tube, microtiter plate, cuvette, membrane, scaffold molecule, thin film, filter paper, disk or chip. The solid phase supports commonly used in the current immunoassay include magnetic microspheres (magnetic beads), microtiter plates, nitrocellulose membranes, polystyrene latexes, and the like.
Taking magnetic microspheres as an example, the magnetic microspheres are uniform spherical particles with superparamagnetism and protective shells, and are basically formed by combining carrier microspheres and ligands. The core is paramagnetic particles, the outer layer of the core is coated with a layer of macromolecules, the outermost layer is a ligand, and the ligand is used for coupling with active groups on target molecules to realize the coating of the target molecules on a solid phase carrier. Typically the target molecule is one of the members of a specific binding pair, such as antigens and antibodies, biotin or derivatives thereof and avidin or derivatives thereof, carbohydrates and lectins, complementary nucleotide sequences, effector and receptor molecules, cofactors and enzymes, enzyme inhibitors and enzymes, digoxigenin and digoxigenin. Taking the double-antibody sandwich method for detecting the antigen as an example, the antibody is coated on the magnetic microsphere, the antibody marked by the marker can be detected by adding a sample to be detected containing the antigen, a magnetic microsphere-antibody-antigen to be detected-antibody-detectable marker compound is formed, and the compound moves directionally under the action of an external magnetic field, so that the purpose of separating and detecting the antigen to be detected is achieved.
In addition, magnetic beads are generally prepared by coupling functional groups such as hydroxyl group (-OH), amino group (-NH), etc. to the outermost layer of the magnetic beads2) Aldehyde group (-CHO), carboxyl group (-COOH), tosyl group, mercapto group (-SH), silicon group and the like, and then coupled with the group of the target molecule; the common magnetic bead coating methods comprise methods such as physical adsorption, covalent coupling, affinity coupling, protein A/protein G directional coupling and the like. Wherein, the physical adsorption is to fix the antibody on the surface of the magnetic bead by the intermolecular force such as electrostatic adsorption, hydrophobic effect and the like; the covalent coupling is to treat antibody protein or solid phase surface functional groups by a specific chemical reagent and fix the antibody on the surface of a substrate by covalent bonds; the most frequently used affinity coupling is a streptavidin-biotin system, wherein streptavidin is covalently coupled with magnetic beads and then forms a complex with an antibody marked by biotin; protein A/protein G directional coupling is to couple protein A or protein G to magnetic beads by using the specific binding of protein A and protein G to the Fc end of protein.
However, in any coupling mode, after the solid support is coupled with the target molecule, some problems with undesirable properties, such as poor clinical specificity, poor stability of the coated product, high CV value (such as jumping pores), and the like, may occur, so that it is important to improve the properties of the coated product.
In view of the above, the present invention is particularly proposed.
Disclosure of Invention
The first objective of the present invention is to provide a method for coating a target molecule on a solid support.
The second purpose of the invention is to provide the coated product obtained by the method.
The third purpose of the invention is to provide the application of the coating product in preparing immunodiagnostic reagents.
The fourth object of the present invention is to provide a kit containing the coated product provided by the present invention.
In order to achieve the above purpose of the present invention, the following technical solutions are adopted:
a method for coating target molecules on a solid support comprises co-coating the target molecules with an inert protein on the solid support to obtain a coated product.
For example, the inert protein includes bovine serum albumin, hemocyanin, ovalbumin, casein, histone, skim milk powder, polylysine, gelatin, or tryptone.
Further, the target molecule comprises one of the members of a specific binding pair comprising antigens and antibodies, biotin and its derivatives and avidin and its derivatives, carbohydrates and lectins, complementary nucleotide sequences, effector and receptor molecules, cofactors and enzymes, enzyme inhibitors and enzymes, or digoxigenin and digoxigenin.
Further, the material of the solid support is, for example, plastic, derivatized plastic, magnetic or non-magnetic metal, or, glass or silicon;
the configuration of the solid support is, for example, a microparticle, bead, test tube, microtiter plate, cuvette, membrane, scaffold molecule, filter paper, disk, or chip;
the solid support is for example a magnetic microparticle, a microtiter plate, a nitrocellulose membrane or a polystyrene latex;
the magnetic fine particles are, for example, carboxyl magnetic beads, amino magnetic beads, NHS magnetic beads, hydroxyl magnetic beads, tosyl magnetic beads, or epoxy magnetic beads.
Further, the mass ratio of the target molecule to the inert protein is (1-8): 1.
further, after activating the solid support, and/or after activating the target molecule and the inert protein, co-coating the target molecule and the inert protein on the solid support;
further, the co-coating also comprises a sealing step to obtain a coated product.
The coated product is prepared by the method.
The application of the coating product in immunodiagnosis or the preparation of immunodiagnosis reagents.
Further, the immunodiagnosis includes immunodetection of infectious disease-associated antigens or antibodies specifically binding to antigens, immunodetection of cardiac markers, immunodetection of tumor-associated markers, immunodetection of inflammatory markers or immunodetection of endocrine-associated antigens;
preferably, the infectious disease includes a viral infectious disease, a bacterial infectious disease, a fungal infectious disease, a chlamydia infectious disease, a mycoplasma infectious disease, or a parasitic infectious disease;
preferably, the infectious disease-associated antigen includes an HIV antigen, a hepatitis A virus antigen, a hepatitis B virus antigen, a hepatitis C virus antigen, a hepatitis D virus antigen, a hepatitis E virus antigen, a hepatitis G virus antigen, a rubella virus antigen, a human cytomegalovirus antigen, a herpes simplex virus type 1 antigen, a herpes simplex virus type 2 antigen, a rabies virus antigen, a human T lymphocyte leukemia virus antigen, a dengue fever virus antigen, a human papilloma virus antigen, a West Nile virus antigen, a forest encephalitis virus antigen, a measles virus antigen, an influenza virus antigen, a parainfluenza virus antigen, a varicella virus antigen, an echovirus antigen, a coxsackie virus antigen, an encephalitis B virus antigen, a coxsackie virus antigen, an EB virus antigen, a mumps virus antigen, a treponema antigen, a hepatitis B virus antigen, a hepatitis C virus antigen, a hepatitis D virus antigen, a, A Borrelia burgdorferi antigen, a Chlamydia trachomatis antigen, a Chlamydia pneumoniae antigen, a Chlamydia psittaci antigen, a ureaplasma urealyticum antigen, a Mycoplasma pneumoniae antigen, a Mycobacterium tuberculosis antigen, a helicobacter pylori antigen, a gonococcal antigen, a Plasmodium antigen, a Trypanosoma cumini antigen or a Toxoplasma antigen;
preferably, the cardiac marker comprises troponin, myoglobin, creatine kinase isozyme, N-terminal brain natriuretic peptide precursor, cardiac fatty acid binding protein, D-dimer, lipoprotein-associated phospholipase a2, myeloperoxidase, or growth stimulating expression gene 2 protein;
preferably, the tumor-associated markers comprise: gastrin releasing peptide precursor, carbohydrate antigen, cytokeratin 19, epididymin 4, alpha-fetoprotein, carcinoembryonic antigen, prostate specific antigen, squamous cell carcinoma antigen, or human prostate specific gene 1;
preferably, the inflammatory marker comprises C-reactive protein, procalcitonin, interleukin 6, serum amyloid a, alpha-antitrypsin, alpha-acid glycoprotein, ceruloplasmin, haptoglobin, C1 esterase inhibitor or alpha 2-macroglobulin.
A kit comprising the above-described coated product.
Compared with the prior art, the invention has the beneficial effects that:
the invention provides a method for coating a target molecule on a solid support, which is to coat the target molecule and inert protein on the solid support to obtain a coated product. The method can reduce incorrect coupling of the solid support and the target molecule through the coating competition relationship by introducing the inert protein and the target molecule to be coated, for example, mutual shielding of the target molecules on the surface of the solid support is reduced, the formation of an alternate arrangement form of the target molecules, the inert protein, the target molecules and the inert protein on the surface of the solid support is facilitated, the structure of the target molecules coupled to the solid support is more correct, the influence of an activating agent on the target molecules is reduced, the influence of chemical reaction generated by participation of the activating agent or violent change of a coating buffer solution on the structure and stability of the target molecules in the coating process is reduced, and the effective coupling efficiency and the stability of a coated product are improved.
The coating product prepared by the method can be applied to immunoassay, and can improve clinical specificity, stability and repeatability.
Detailed Description
Embodiments of the present invention will be described in detail below with reference to examples, but it will be understood by those skilled in the art that the following examples are only illustrative of the present invention and should not be construed as limiting the scope of the present invention. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer.
Unless otherwise defined, technical and scientific terms used herein have the same meaning as is familiar to those skilled in the art. In addition, any methods or materials similar or equivalent to those described herein can also be used in the present invention.
A method for coating target molecules on a solid support comprises co-coating the target molecules with an inert protein on the solid support to obtain a coated product.
The method introduces the inert protein, and the inert protein and the target molecule are coated on the solid support together, so that incorrect coupling of the solid support and the target molecule can be reduced in a coating competition mode, for example, mutual shielding of the target molecule on the surface of the solid support is reduced, the formation of an alternate arrangement form of the target molecule, the inert protein, the target molecule and the inert protein on the surface of the solid support is facilitated, the structure of the target molecule coupled on the solid support is more correct, the influence of an activating agent on the target molecule is reduced, the influence of chemical reaction generated by participation of the activating agent or violent change of a coating buffer solution on the structure and stability of the target molecule in the coating process is reduced, and the effective coupling efficiency and the stability of a coating product are improved. The obtained coating product can be applied to immunoassay, and can improve clinical specificity, stability and repeatability.
In the present invention, "co-coating" means that the target molecule and the inert protein are coated on the same solid support as a coating, for example, the target molecule and the inert protein are mixed and subjected to a coating reaction with the solid support. The coating reaction between the target molecule and the solid support in the present invention may be a coating technique which is conventional in the art, and is not particularly limited. In the preparation of solid supports, such as products coated with magnetic beads, a mixture of inert proteins and target molecules may be coated with magnetic beads.
Inert protein in the present invention refers to a protein that does not react with the immune reaction system, and may be, for example, but not limited to, bovine serum albumin, hemocyanin, ovalbumin, casein, histone, skim milk powder, polylysine, gelatin, tryptone, or the like.
The target molecule of the present invention is a substance that is conventional in the art for coating with a solid support and may be one of the members of a specific binding pair, which may be, for example, antigens and antibodies, biotin and its derivatives and avidin and its derivatives, carbohydrates and lectins, complementary nucleotide sequences, effector and receptor molecules, cofactors and enzymes, enzyme inhibitors and enzymes, or digoxigenin and digoxigenin, and the like. It is understood that "the target molecule is one of the members of a specific binding pair" in the present invention means, for example, when the specific binding pair is an antigen and an antibody, the target molecule is an antigen or an antibody, and may be either an antigen or an antibody; for example, when the specific binding pair is a carbohydrate or a lectin, the target molecule may be a carbohydrate or a lectin, or may be a carbohydrate or a lectin.
The solid support in the present invention refers to a solid phase carrier commonly used in the art, and the material can be, for example, plastic (e.g., polystyrene, polyvinyl chloride, etc.), derivatized plastic, magnetic or non-magnetic metal, glass or silicon, etc.; the configuration may be, for example, a particle, bead, test tube, microtiter plate, cuvette, membrane, scaffold molecule, filter paper, disk or chip, or the like; the solid support may be, for example, magnetic microspheres (magnetic beads), microtiter plates, nitrocellulose membranes, polystyrene latexes, etc., which are commonly used in the art. The solid support is a magnetic particle, such as a carboxyl magnetic bead, an amino magnetic bead, an NHS magnetic bead, a hydroxyl magnetic bead, a tosyl magnetic bead, or an epoxy magnetic bead.
In a preferred embodiment, the mass ratio of target molecule to inert protein is (1-8): 1. the mass ratio of target molecule to inert protein is typically, but not limited to, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1 or 8: 1.
In a preferred embodiment, the ratio of the target molecule to the solid support can be used in an amount that is conventional in the art, and is not particularly limited herein. Preferably, the mass ratio of target molecule to solid support is 1: (10-100), further 1: (45-55). The mass ratio of target molecule to solid support is typically, but not limited to, 1:10, 1:20, 1:30, 1:40, 1:45, 1:47, 1:50, 1:52, 1:55, 1:60, 1:70, 1:80, 1:90 or 1: 100.
In a preferred embodiment, the target molecule is co-coated with the inert protein on the solid support after activation of the solid support and/or after activation of the target molecule and inert protein. Before the target molecule and the inert protein are coated on the solid support, the method further comprises the step of activating the solid support, or activating the target molecule and the inert protein, or activating the solid support, the target molecule and the inert protein.
In a preferred embodiment, after the target molecule and the inert protein are co-coated on the solid support, the method further comprises the step of blocking the solid support to obtain a coated product. The blocking in the present invention may be a blocking method which is conventional in the art, and is not particularly limited, and it is preferable to block the solid support using bovine serum albumin, gelatin, casein or the like.
The coating product prepared by the method is applied to immunoassay, and can improve clinical specificity, stability and repeatability.
The application of the coating product in immunodiagnosis or the preparation of immunodiagnosis reagents.
In preferred embodiments, the immunodiagnosis comprises immunodetection of an infectious disease-associated antigen or an antibody that specifically binds to an antigen, immunodetection of a cardiac marker, immunodetection of a tumor-associated marker, immunodetection of an inflammation marker, or immunodetection of an endocrine-associated antigen.
Preferably, the infectious disease includes a viral infectious disease, a bacterial infectious disease, a fungal infectious disease, a chlamydia infectious disease, a mycoplasma infectious disease or a parasitic infectious disease.
Preferably, the infectious disease-associated antigens include HIV antigens, hepatitis A virus antigens, hepatitis B virus antigens, hepatitis C virus antigens, hepatitis D virus antigens, hepatitis E virus antigens, hepatitis G virus antigens, rubella virus antigens, human cytomegalovirus antigens, herpes simplex virus type 1 antigens, herpes simplex virus type 2 antigens, rabies virus antigens, human T lymphocyte leukemia virus antigens, dengue fever virus antigens, human papilloma virus antigens, West Nile virus antigens, forest encephalitis virus antigens, measles virus antigens, influenza virus antigens, parainfluenza virus antigens, varicella virus antigens, echovirus antigens, coxsackievirus antigens, encephalitis B virus antigens, coxsackievirus antigens, EB virus antigens, mumps virus antigens, treponema antigens, Borrelia burgdorferi antigen antigens, Epicosaxiella virus antigens, Epstein-Barr virus antigens, hepatitis B virus antigens, hepatitis C virus antigens, hepatitis D antigens, herpes simplex virus antigens, chlamydia trachomatis antigen, Chlamydia pneumoniae antigen, Chlamydia psittaci antigen, ureaplasma urealyticum antigen, Mycoplasma pneumoniae antigen, Mycobacterium tuberculosis antigen, helicobacter pylori antigen, gonococcus antigen, Plasmodium falciparum antigen, Trypanosoma cruzi antigen or Toxoplasma gondii antigen.
Preferably, the cardiac marker comprises troponin, myoglobin, creatine kinase isozyme, N-terminal brain natriuretic peptide precursor, cardiac fatty acid binding protein, D-dimer, lipoprotein-associated phospholipase a2, myeloperoxidase, or growth stimulating expression gene 2 protein.
Preferably, the tumor-associated markers comprise: gastrin releasing peptide precursor, carbohydrate antigen, cytokeratin 19, epididymin 4, alpha-fetoprotein, carcinoembryonic antigen, prostate specific antigen, squamous cell carcinoma antigen, or human prostate specific gene 1.
Preferably, the inflammatory marker comprises C-reactive protein, procalcitonin, interleukin 6, serum amyloid a, alpha-antitrypsin, alpha-acid glycoprotein, ceruloplasmin, haptoglobin, C1 esterase inhibitor or alpha 2-macroglobulin.
The invention finally provides a kit comprising the above-described coated product.
The invention is further illustrated by the following specific examples, which, however, are to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.
Example 1 coating of carboxyl magnetic beads for HIV project
1) HIV-I (Phoenix organism) 2mg/mL × 1.0mL dialyzed into activation buffer (50mM MES pH5.5);
2) taking magnetic beads Merck EM 1-100/400.1 mL (100mg/mL,10mg), washing with activation buffer (50mM MES pH5.5) for 3 times, each time 2mL, finally adding 1mL of activation buffer, and ultrasonically dispersing;
3) 3mg EDC was weighed and dissolved in 0.3mL of activation buffer (2-8 ℃ pre-cooled) to 10mg/mL to obtain the activator. Immediately adding 0.2mL of activator (about 100mM EDC) to the mixture of magnetic beads under shaking, mixing well, rotating at room temperature (30rpm) for 0.5-1 hr, magnetically separating, discarding the supernatant, and resuspending activated carboxyl magnetic beads with 0.5mL of 50mM MES with pH 5.5;
4) adding 0.2mg HIV-I antigen into 2ml 50mM MES with pH5.5, adding 10 μ l 10mg/ml BSA water solution, and mixing to obtain mixture of target molecule and inert protein;
5) mixing the activated carboxyl magnetic beads resuspended in the step 3) with the mixed solution obtained in the step 4), and reacting for 2 hours at room temperature;
6) washing with washing solution (50mM Tris-HCl, 150mM NaCl, 0.05% Tween-20, 0.1% ProClin 300, pH7.4) for 2 times, 3mL each time; adding 3mL of blocking solution (washing solution + 1% BSA), and reacting at room temperature for 2 hours;
7) washing with 3 times of 3mL of washing solution each time; finally adding 1mL of carboxyl magnetic bead preservation solution for resuspension, wherein the final concentration is 10mg/mL of solid content. Storing at 2-8 ℃.
Example 2 coating of amino magnetic beads for TP project
1) 10mg of amino magnetic beads (merck) were washed 3 times with 1 XPBS, and 0.9mL of 1 XPBS was added to resuspend the mixture at 10 mg/mL. SMCC ((N-maleimidomethyl) cyclohexane-1-carboxylic acid succinimidyl ester) was weighed out and dissolved in DMF (N, N-dimethylformamide) at 12 mM/L; 2mg of 2IT (2-Iminothiolane hydrochloride, 2-Iminothiolane HCl) was weighed out and dissolved in 1 XPBS to 10 mM/L. Adding 100. mu.L of SMCC into the resuspended amino magnetic beads, mixing, adding 10. mu.L of 2IT solution into the amino magnetic bead mixture, mixing, and performing rotary incubation at 25 ℃ for 30 min.
2) Taking 0.2mg of TP-17 antigen, adding the TP-17 antigen into 1ml of 1 XPBS, then adding 10 mu l of 10mg/ml BSA water solution, and uniformly mixing to obtain a mixed solution of a target molecule and inert protein;
3) the activated amino magnetic beads were washed 1 time with 1 XPBS and resuspended in 0.5ml of 1 XPBS.
4) Mixing the mixed solution obtained in the step 2) with the activated amino magnetic beads obtained in the step 3), uniformly mixing, and incubating at room temperature for 2 hours;
5) washing with washing solution (50mM Tris-HCl +150mM NaCl + 0.05% Tween-20+ 0.1% ProClin 300, pH7.4) for 2 times, 3mL each time; adding 3mL of blocking solution (washing solution + 1% BSA), and reacting at room temperature for 2 hours;
6) washing with 3 times of 3mL of washing solution each time; finally adding 1mL of amino magnetic bead preservation solution for resuspension, wherein the final concentration is 10mg/mL of solid content. Storing at 2-8 ℃.
Example 3 coating of carboxyl magnetic beads for HIV project
The preparation method of the product coated with magnetic beads in this embodiment can be seen in the steps in embodiment 1, except that in step 4): 0.2mg of HIV-I antigen was added to 2ml of 50mM MES pH5.5, and 20. mu.l of 10mg/ml BSA aqueous solution was added thereto and mixed well to obtain a mixture of the target molecule and the inert protein.
Example 4 coating of carboxyl magnetic beads for HIV project
The preparation method of the product coated with magnetic beads in this embodiment can be seen in the steps in embodiment 1, except that in step 4): 0.2mg of HIV-I antigen was added to 2ml of 50mM MES pH5.5, and then 2.5. mu.l of 10mg/ml BSA aqueous solution was added thereto and mixed well to obtain a mixture of the target molecule and inert protein.
Example 5 coating of amino magnetic beads for TP project
The preparation method of the magnetic bead-coated product in this embodiment can be seen in the steps in embodiment 2, except that in step 2): 0.2mg of TP-17 antigen is added into 1ml of 1 XPBS, and then 20 mul of 10mg/ml BSA water solution is added and mixed evenly to obtain the mixed solution of the target molecule and the inert protein.
Example 6 coating of amino magnetic beads for TP project
The preparation method of the magnetic bead-coated product in this embodiment can be seen in the steps in embodiment 2, except that in step 2): 0.2mg of TP-17 antigen is added into 1ml of 1 XPBS, and then 2.5 mul of 10mg/ml BSA water solution is added and mixed evenly to obtain the mixed solution of the target molecule and the inert protein.
Example 7 coating of carboxyl magnetic beads for HIV project
The preparation method of the product coated with magnetic beads in this embodiment can be seen in the steps in embodiment 1, except that in step 4): 0.2mg of HIV-I antigen was added to 2ml of 50mM MES pH5.5, and 10. mu.l of a 10mg/ml casein aqueous solution was added thereto and mixed well to obtain a mixture of the objective molecule and the inert protein.
Example 8 coating of amino magnetic beads for TP project
The preparation method of the magnetic bead-coated product in this embodiment can be seen in the steps in embodiment 2, except that in step 2): 0.2mg of TP-17 antigen is taken and added into 1ml of 1 XPBS, then 10 mul of 10mg/ml gelatin water solution is added, and the mixture is evenly mixed to obtain the mixed solution of the target molecule and the inert protein.
Comparative example 1 coating of carboxyl magnetic beads for HIV project
1) HIV-I (Fei Peng biological self-production) 2mg/mL × 1.0mL dialysis to activation buffer (50mM MES pH5.5);
2) taking magnetic beads Merck EM 1-100/400.1 mL (100mg/mL,10mg), washing with activation buffer (50mM MES pH5.5) for 3 times, each time 2mL, finally adding 1mL of activation buffer, and ultrasonically dispersing;
3) 3mg EDC was weighed and dissolved in 0.3mL of activation buffer (2-8 ℃ pre-cooled) to 10mg/mL to obtain the activator. Immediately adding 0.2mL of activator (about 100mM EDC) to the mixture of magnetic beads under shaking, mixing well, rotating at room temperature (30rpm) for 0.5-1 hr, magnetically separating, discarding the supernatant, and resuspending activated carboxyl magnetic beads with 0.5mL of 50mM MES with pH 5.5;
4) adding 0.2mg HIV-I antigen into 2ml 50mM MES (pH5.5), and mixing;
5) mixing the activated carboxyl magnetic beads resuspended in the step 3) with the mixed solution obtained in the step 4), and reacting for 2 hours at room temperature;
6) washing with washing solution (50mM Tris-HCl, 150mM NaCl, 0.05% Tween-20, 0.1% ProClin 300, pH7.4) for 2 times, 3mL each time; adding 3mL of blocking solution (washing solution + 1% BSA), and reacting at room temperature for 2 hours;
7) washing with 3 times of 3mL of washing solution each time; finally adding 1mL of carboxyl magnetic bead preservation solution for resuspension, wherein the final concentration is 10mg/mL of solid content. Storing at 2-8 ℃.
Comparative example 2 coating of amino magnetic beads for TP project
1) 10mg of amino magnetic beads (merck) were washed 3 times with 1 XPBS, and 0.9mL of 1 XPBS was added to resuspend the mixture at 10 mg/mL. SMCC ((N-maleimidomethyl) cyclohexane-1-carboxylic acid succinimidyl ester) was weighed out and dissolved in DMF (N, N-dimethylformamide) at 12 mM/L; 2mg of 2IT (2-Iminothiolane hydrochloride, 2-Iminothiolane HCl) was weighed out and dissolved in 1 XPBS to 10 mM/L. Adding 100. mu.L of SMCC into the resuspended amino magnetic beads, mixing, adding 10. mu.L of 2IT solution into the amino magnetic bead mixture, mixing, and performing rotary incubation at 25 ℃ for 30 min.
2) Taking 0.2mg of TP-17 antigen, adding the TP-17 antigen into 1ml of 1 multiplied by PBS, and uniformly mixing;
3) the activated amino magnetic beads were washed 1 time with 1 XPBS and resuspended in 0.5ml of 1 XPBS.
4) Mixing the mixed solution obtained in the step 2) with the activated amino magnetic beads obtained in the step 3), uniformly mixing, and incubating at room temperature for 2 hours;
5) washing with washing solution (50mM Tris-HCl +150mM NaCl + 0.05% Tween-20+ 0.1% ProClin 300, pH7.4) for 2 times, 3mL each time; adding 3mL of blocking solution (washing solution + 1% BSA), and reacting at room temperature for 2 hours;
6) washing with 3 times of 3mL of washing solution each time; finally adding 1mL of amino magnetic bead preservation solution for resuspension, wherein the final concentration is 10mg/mL of solid content. Storing at 2-8 ℃.
Test example 1 clinical specificity
The evaluation method comprises the following steps: the magnetic bead coating products in examples 1-2 (inventive process) and comparative examples 1-2 (prior art process) were respectively matched with corresponding acridinium ester marker working solutions to perform serum sample comparison by a double-antigen sandwich method.
The magnetic particle chemiluminescence detection is adopted, and the coated magnetic beads are prepared into working solution, positive quality control substances, negative quality control substances, other clinical specimens and acridinium ester marker working solution according to the principle of double-antigen sandwich detection antibodies. The experimental process comprises the following steps: adding 100 mul of samples (positive quality control, negative quality control and clinical samples) into a reaction cup, uniformly mixing 50 mul of magnetic bead working solution, incubating for 15 min/magnetic separation, washing for 4 times by using 1 XPBST cleaning solution/adding 100 mul of acridinium ester working solution, oscillating, uniformly mixing, incubating for 10min at 37 degrees/magnetic separation, washing for 4 times by using 1 XPBST cleaning solution/adding 100 mul of excitation solution A, adding 100 mul of excitation solution B, and testing the luminous value by using a luminometer.
The results are as follows:
the conclusion is drawn from the above data: the magnetic bead coated product obtained by the method for coating the target molecules by the magnetic beads is obviously improved in the clinical specificity of HIV and TP projects, and the false positive detection rate is obviously reduced.
Test example 2 stability
The evaluation method comprises the following steps: the magnetic bead coating products obtained in examples 1-8 and comparative examples 1-2 were all prepared as working solutions, i.e., diluted 40 times with the magnetic bead coating product preservation solution, and each sample was independently divided into 3 tubes, each tube containing 4 ml. The samples were stored at 2-8 ℃ for accelerated testing at 37 ℃ for 3 days (37 ℃ incubator on day 4) and at 37 ℃ for 7 days (37 ℃ incubator on day 0). On the seventh day, samples of 3 days and 7 days at 37 ℃ were taken, and the samples were equilibrated to room temperature with the samples of 2 to 8 ℃ to conduct detection while simultaneously testing the activity in the same manner as in test example 1.
The following data lead to conclusions: the magnetic bead coated product obtained by the method for coating the target molecules by the magnetic beads is improved in the stability of the magnetic bead coated product of HIV and TP.
Test example 3 repeatability
The method comprises the following steps: the negative quality control and the positive quality control were subjected to 12-well repeated sample addition to test the inter-well reproducibility, i.e., inter-well CV, in the same manner as in test example 1. The following data can be used for concluding that the CV of negative quality control and positive quality control is greatly improved on two projects of HIV and TP by the method for coating the target molecules by the magnetic beads, and the phenomenon of hole jumping is obviously improved.
Comparative example 3 BSA coated carboxyl magnetic bead
BSA and carboxyl magnetic particles are coupled by a chemical crosslinking method, and the steps are as follows:
1) BSA 2mg/mL × 1.0mL dialyzed into activation buffer (50mM MES pH 5.5);
2) taking Merck EM 1-100/400.1 mL (100mg/mL,10mg), washing with activation buffer (50mM MES pH5.5) for 3 times, each time 2mL, finally adding 1mL of activation buffer, and ultrasonically dispersing;
3) 3mg of EDC was weighed and dissolved in 0.3mL of activation buffer (2-8 deg.C pre-cooled) to 10 mg/mL. Immediately, 0.2mL of EDC (about 100mM EDC) solution was added to the mixture under shaking and mixed well. Rotating at room temperature (30rpm) for reaction for 0.5-1 hour, carrying out magnetic separation, and removing a supernatant; resuspended with 0.5ml 50mM MES pH 5.5;
4) adding 0.2mg dialyzed BSA to 2ml 50mM MES pH5.5, and mixing;
5) mixing the resuspended magnetic beads with diluted BSA, and rotating (30rpm) at room temperature to react for 2 hours;
6) washing with washing solution (50mM Tris-HCl +150mM NaCl + 0.05% Tween-20+ 0.1% ProClin 300, pH7.4) for 2 times, 3mL each time; 3mL of blocking solution (Wash + 1% BSA) was added and the reaction was spun at room temperature (30rpm) for 2 hours;
7) washing with 3 times of 3mL of washing solution each time; finally adding 1mL of magnetic bead preservation solution for resuspension, wherein the final concentration is 10mg/mL of solid content. And preserving at +2 to +8 ℃.
The coated magnetic beads of comparative example 1 were mixed with the coated magnetic beads of this comparative example to perform an activity test.
And the effect of mixing and using the BSA coated magnetic beads and the antigen coated magnetic beads is verified.
As can be seen from the table, after BSA magnetic beads are added, the activity is not improved, the background is not improved, but the clinical background is worsened, CV is obviously increased, and the hole jumping occurs.
While particular embodiments of the present invention have been illustrated and described, it would be obvious that various other changes and modifications can be made without departing from the spirit and scope of the invention. It is therefore intended to cover in the appended claims all such changes and modifications that are within the scope of this invention.
Claims (10)
1. A method for coating a target molecule on a solid support, comprising co-coating the target molecule with an inert protein on the solid support to obtain a coated product.
2. The method of claim 1, wherein the inert protein comprises bovine serum albumin, hemocyanin, ovalbumin, casein, histone, skim milk powder, polylysine, gelatin, or tryptone.
3. The method of claim 1, wherein the target molecule comprises one of the members of a specific binding pair comprising antigens and antibodies, biotin and its derivatives and avidin and its derivatives, carbohydrates and lectins, complementary nucleotide sequences, effector and receptor molecules, cofactors and enzymes, enzyme inhibitors and enzymes, or digoxigenin and digoxigenin.
4. The method of claim 1, wherein the solid support is made of a material such as plastic, derivatized plastic, magnetic or non-magnetic metal, or glass or silicon;
the configuration of the solid support is, for example, a microparticle, bead, test tube, microtiter plate, cuvette, membrane, scaffold molecular filter, disk, or chip;
the solid support is for example a magnetic microparticle, a microtiter plate, a nitrocellulose membrane or a polystyrene latex;
the magnetic fine particles are, for example, carboxyl magnetic beads, amino magnetic beads, NHS magnetic beads, hydroxyl magnetic beads, tosyl magnetic beads, or epoxy magnetic beads.
5. The method of claim 1, wherein the mass ratio of the target molecule to the inert protein is (1-8): 1.
6. the method of any one of claims 1 to 5, wherein the target molecule and the inert protein are co-coated on the solid support after activation of the solid support and/or after activation of the target molecule and the inert protein;
preferably, the co-coating step is followed by a blocking step to obtain a coated product.
7. A coated product prepared by the process of any one of claims 1 to 6.
8. Use of the coated product of claim 7 in immunodiagnostics or in the preparation of immunodiagnostic reagents.
9. The use of claim 8, wherein said immunodiagnosis comprises immunodetection of an infectious disease-associated antigen or an antibody specifically binding to an antigen, immunodetection of a cardiac marker, immunodetection of a tumor-associated marker, immunodetection of an inflammatory marker or immunodetection of an endocrine-associated antigen;
preferably, the infectious disease includes a viral infectious disease, a bacterial infectious disease, a fungal infectious disease, a chlamydia infectious disease, a mycoplasma infectious disease, or a parasitic infectious disease;
preferably, the infectious disease-associated antigen includes an HIV antigen, a hepatitis A virus antigen, a hepatitis B virus antigen, a hepatitis C virus antigen, a hepatitis D virus antigen, a hepatitis E virus antigen, a hepatitis G virus antigen, a rubella virus antigen, a human cytomegalovirus antigen, a herpes simplex virus type 1 antigen, a herpes simplex virus type 2 antigen, a rabies virus antigen, a human T lymphocyte leukemia virus antigen, a dengue fever virus antigen, a human papilloma virus antigen, a West Nile virus antigen, a forest encephalitis virus antigen, a measles virus antigen, an influenza virus antigen, a parainfluenza virus antigen, a varicella virus antigen, an echovirus antigen, a coxsackie virus antigen, an encephalitis B virus antigen, a coxsackie virus antigen, an EB virus antigen, a mumps virus antigen, a treponema antigen, a hepatitis B virus antigen, a hepatitis C virus antigen, a hepatitis D virus antigen, a, A Borrelia burgdorferi antigen, a Chlamydia trachomatis antigen, a Chlamydia pneumoniae antigen, a Chlamydia psittaci antigen, a ureaplasma urealyticum antigen, a Mycoplasma pneumoniae antigen, a Mycobacterium tuberculosis antigen, a helicobacter pylori antigen, a gonococcal antigen, a Plasmodium antigen, a Trypanosoma cumini antigen or a Toxoplasma antigen;
preferably, the cardiac marker comprises troponin, myoglobin, creatine kinase isozyme, N-terminal brain natriuretic peptide precursor, cardiac fatty acid binding protein, D-dimer, lipoprotein-associated phospholipase a2, myeloperoxidase, or growth stimulating expression gene 2 protein;
preferably, the tumor-associated markers comprise: gastrin releasing peptide precursor, carbohydrate antigen, cytokeratin 19, epididymin 4, alpha-fetoprotein, carcinoembryonic antigen, prostate specific antigen, squamous cell carcinoma antigen, or human prostate specific gene 1;
preferably, the inflammatory marker comprises C-reactive protein, procalcitonin, interleukin 6, serum amyloid a, alpha-antitrypsin, alpha-acid glycoprotein, ceruloplasmin, haptoglobin, C1 esterase inhibitor or alpha 2-macroglobulin.
10. A kit comprising the coated product of claim 8.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911238160.9A CN112924666A (en) | 2019-12-05 | 2019-12-05 | Solid support coating product, preparation method, application and product thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911238160.9A CN112924666A (en) | 2019-12-05 | 2019-12-05 | Solid support coating product, preparation method, application and product thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112924666A true CN112924666A (en) | 2021-06-08 |
Family
ID=76161283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911238160.9A Pending CN112924666A (en) | 2019-12-05 | 2019-12-05 | Solid support coating product, preparation method, application and product thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112924666A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112798790A (en) * | 2020-12-24 | 2021-05-14 | 深圳市科曼医疗设备有限公司 | Kit for determining concentration of C-reactive protein and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1486826A (en) * | 1973-08-30 | 1977-09-28 | Gen Electric | Method for conducting surface immunological tests |
| CN101356438A (en) * | 2005-11-24 | 2009-01-28 | 根田股份有限公司 | Turbidimetric immunoassay for assessing human cysteine proteinase inhibitor C |
| CN109444437A (en) * | 2018-12-19 | 2019-03-08 | 广东菲鹏生物有限公司 | Miao's Le Shi pipe hormone determination kit based on restoring method label attached luminescent indicator |
| CN109613240A (en) * | 2019-01-04 | 2019-04-12 | 广东菲鹏生物有限公司 | It is a kind of for detecting the kit of HIV |
-
2019
- 2019-12-05 CN CN201911238160.9A patent/CN112924666A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1486826A (en) * | 1973-08-30 | 1977-09-28 | Gen Electric | Method for conducting surface immunological tests |
| CN101356438A (en) * | 2005-11-24 | 2009-01-28 | 根田股份有限公司 | Turbidimetric immunoassay for assessing human cysteine proteinase inhibitor C |
| CN109444437A (en) * | 2018-12-19 | 2019-03-08 | 广东菲鹏生物有限公司 | Miao's Le Shi pipe hormone determination kit based on restoring method label attached luminescent indicator |
| CN109613240A (en) * | 2019-01-04 | 2019-04-12 | 广东菲鹏生物有限公司 | It is a kind of for detecting the kit of HIV |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112798790A (en) * | 2020-12-24 | 2021-05-14 | 深圳市科曼医疗设备有限公司 | Kit for determining concentration of C-reactive protein and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4053092B2 (en) | Method for isolating, in particular detecting or quantifying an analyte in a medium | |
| US5571726A (en) | Kit containing glutaraldehyde coated colloidal metal particles of a preselected size | |
| JP6438483B2 (en) | Novel diagnostic assay using magnetic particles | |
| IE61365B1 (en) | A solid phase system for use in ligand-receptor assays | |
| IE75725B1 (en) | Ligand gold bonding | |
| JP5401724B2 (en) | Biosensing method using coated magnetic fine particles and biosensing device used in the method | |
| JPH02156155A (en) | Measurement and reagent for specifically bonding substance | |
| AU648625B2 (en) | Test method and reagent kit therefor | |
| US20080268481A1 (en) | Sensitive Magnetic Catch Assay By Building a Strong Binding Couple | |
| WO2017206713A1 (en) | Method for coupling magnetic particles with antibody molecules | |
| CN111381024A (en) | Immunocapture composition, preparation method, kit and application | |
| US20200326338A1 (en) | Detection agent for bioassay and signal amplification method using same | |
| CN112924666A (en) | Solid support coating product, preparation method, application and product thereof | |
| CN112763703B (en) | Immunomagnetic bead and preparation method and application thereof | |
| US20020110846A1 (en) | Amplified array analysis method and system | |
| JPH07504987A (en) | Method for measuring binding affinity using magnetically labeled binding elements | |
| JP4879067B2 (en) | Sample preparation solution for immunoassay, reagent kit for immunoassay, and immunoassay method | |
| JPH07151759A (en) | Reagent for acquiring reactant, intermediate thereof and acquiring method | |
| CN111983221B (en) | Surface-modified magnetic bead and preparation method and application thereof | |
| CN114062665B (en) | Trace particle marked target molecule and preparation method and application thereof | |
| WO2007115444A1 (en) | Seperation or analysis composition comprising active nanostructure and seperation or analysis method | |
| CN113049811A (en) | Nano magnetic bead coating material, preparation method thereof, detection reagent and detection kit | |
| JP2017508961A5 (en) | ||
| US8153367B2 (en) | Amplified array analysis system | |
| JP5559465B2 (en) | Avidin binding carrier, method for producing the same and method for using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |